Company Encyclopedia
View More
name
Savara
SVRA.US
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
1.946 T
SVRA.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Officer Wasfi Surrenders 21,992 Of Savara Inc [SVRA]

    Officer Wasfi Yasmine of Savara Inc surrendered 21,992 shares back to the company to cover option exercise costs and tax liabilities, as disclosed in a Form 4 filed with the SEC on December 4, 2025. The shares were valued at $140,089, with an ending holding of 168,008 shares directly.

    Reuters·
    US
    SVRA
    +1.11%
    Reuters·
    US
    SVRA
    +1.11%

    Dir Elam Acquires 4,387 Of Savara Inc [SVRA]

    Elam Nevan C, Director of Savara Inc, filed a Form 4 with the SEC, disclosing changes in ownership. On December 2, 2025, he exercised 5,860 shares at $1.46 and surrendered 1,473 shares at $5.81 to cover option exercise costs and tax liabilities. His ending holdings are 66,887 shares directly. The Washington Service offers insider trading analysis and data services.

    Reuters·
    US
    SVRA
    +1.11%
    Reuters·
    US
    SVRA
    +1.11%

    Savara Inc. Unveils New Therapies Targeting Rare Respiratory Diseases

    Savara Inc. has released a corporate presentation detailing its efforts to develop new therapies for rare respiratory diseases, focusing on autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The lead investigational candidate, MOLBREEVI (molgramostim inhalation solution), has conditional trade name acceptance but is not yet approved. Savara plans to resubmit a Biologics License Application (BLA) for MOLBREEVI in December 2025. The presentation also highlights the challenges of current treatments and the need for alternatives.

    Reuters·
    US
    SVRA
    +1.11%
    Reuters·
    US
    SVRA
    +1.11%

    Savara Inc. and PARI Granted European Patent Covering MOLBREEVI and eFlow Nebulizer Combination

    Savara Inc. and PARI have been granted a European patent for the combination of Savara’s investigational therapy, MOLBREEVI, and PARI’s eFlow Nebulizer System. The patent provides protection until March 2043. MOLBREEVI is being developed for autoimmune pulmonary alveolar proteinosis (PAP) and has received several regulatory designations. Upon approval, the eFlow Nebulizer System will be marketed as the Vespera Nebulizer System for use with MOLBREEVI.

    Reuters·
    US
    SVRA
    +1.11%
    Reuters·
    US
    SVRA
    +1.11%

    Savara Inc. to Participate in Piper Sandler Healthcare Conference

    Savara Inc., a biopharmaceutical company, will participate in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, and the Evercore ISI 8th Annual Healthcare Conference on December 4, 2025. The management team will also conduct one-on-one meetings at these events. This information was originally published by Savara Inc. via Business Wire.

    Reuters·
    US
    SVRA
    +1.11%
    Reuters·
    US
    SVRA
    +1.11%
    © 2025 Longbridge｜Disclaimer